Bank of America’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

Bank of America's EUCRW Position: Q2 2023 in Review

Bank of America sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q2 2023, closing a stake of 215 shares — an estimated $7 sold.

Bank of America first reported a position in EUCRW in Q1 2023 and held it in 1 quarter. The position peaked at $7 in Q1 2023. 0 funds tracked by Wall St. Rank hold EUCRW as of Q2 2023.

• Bank of America reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q2 2023 after selling out during the quarter.
• Bank of America sold 215 Eucrates Biomedical Acquisition Corp. Warrant shares in Q2 2023, an estimated $7.
• Bank of America first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q1 2023 and held it in 1 quarter.
• Bank of America's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $7 in Q1 2023.
• 0 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q2 2023.

Based on Bank of America's 13F filing for Q2 2023, filed 14 Aug 2023.